Cadmus raises $4.49M for canine gum disease treatment
What's the deal? New Zealand's Cadmus Animal HealthDealroom has a profile for this one. Try Dealroom → has raised US$5.18M in an early-stage venture round to fund the next phase of its US canine development programme for periodontal disease. The round included a clinical study and manufacturing process development.
Who's backing it? Existing investors Brandon Capital and Booster NZDealroom has a profile for this one. Try Dealroom → took part, joined by new backers Digitalis VenturesDealroom has a profile for this one. Try Dealroom →, Arrow VenturesDealroom has a profile for this one. Try Dealroom →, and MovacDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Cadmus, formed in 2021, is developing an immunotherapeutic to treat chronic periodontal disease in companion animals. Booster Investment ManagementDealroom has a profile for this one. Try Dealroom → added the startup to its Booster Innovation FundDealroom has a profile for this one. Try Dealroom → portfolio in August 2025.
The signal: The raise sits in the mid-range for deals of its kind, a modest sum reflecting the early clinical stage of its work. For companion-animal health, it marks a bet that immunotherapy can address a chronic condition that remains common in dogs.
Read more: efeedlink.com
Image credit: U.S. Department of Energy
